Background/Aims: Hyperphosphatemia is common in patients on hemodialysis. The efficacy
of lanthanum carbonate (LC) in the treatment of hyperphosphatemia in these patients …

Background The effects of lanthanum carbonate (LC) vs. calciumbased phosphate binders
in dialysis patients have been a matter of debate. Methods We electronically searched …

Aim: To assess the effect and safety of lanthanum carbonate (LC) for hypophosphatemia in
patients with end-stage renal disease (ESRD). Methods: According to the collaborative …

Background Hyperphosphatemia increases the risk of adverse outcomes in patients with
end-stage renal disease. It is commonly counteracted with aluminum or calcium salts, which …

Importance Among patients with hyperphosphatemia undergoing dialysis, it is unclear
whether non–calcium-based phosphate binders are more effective than calcium-based …

Background Lanthanum carbonate is a non-calcium phosphate binder that is effective for the
treatment of hyperphosphatemia. However, it is unknown whether treatment with lanthanum …

Objective: To evaluate the efficacy and tolerability of lanthanum carbonate (LC) in the
treatment of hyperphosphatemia in dialysis patients. Method: Multiple databases were used …

Background High levels of serum phosphorus both at baseline and during follow-up are
associated with increased mortality in dialysis patients, and administration of phosphate …

In hemodialysis patients, mineral and bone disorder is an important risk factor for
cardiovascular disease and subsequent death through the progression of vascular …

BACKGROUND: Hyperphosphatemia is a common and potentially harmful condition in
patients with end-stage kidney disease. In Canada, first-line treatment of …